Suggestions
Mark Kotter
Clinician, scientist & entrepreneur transitioning biology to engineering for the benefit of patients.
Mark Kotter is a distinguished neurosurgeon, stem cell biologist, and successful entrepreneur dedicated to enhancing patient outcomes.
His groundbreaking work combines synthetic and stem cell biology, resulting in the development of revolutionary technology that streamlines the production of human cells for various applications like research, drug development, and cell therapies.
Mark is the visionary founder of the acclaimed synthetic cell company bit bio and a co-founder of the innovative cultured meat startup Meatable.
His impressive educational background includes a Doctor of Philosophy (PhD) and a Master of Philosophy (MPhil) from the prestigious University of Cambridge, as well as a Doctor of Medicine (MD) with Distinction from Karl-Franzens-Universität Graz / University of Graz.
Throughout his career, Mark has held key positions in renowned organizations such as NIHR Clinician Scientist at University of Cambridge, Professeur Invité at Université Paris Descartes, Co-Founder at Meatable, and various roles in pioneering initiatives like the Spinal Cord Injury Forum at AOSpine and the NIHR Brain Injury MedTech Co-operative.
His extensive experience also includes leadership roles as Founder of bit bio, Founder of Myelopathy.org, Clinical Lecturer in Neurosurgery at University of Cambridge, and Research Group Leader at the Max Planck Institute for Experimental Medicine.
Mark's expertise and relentless dedication to advancing medical and biological sciences make him a prominent figure in the fields of neurosurgery, stem cell biology, and entrepreneurship.
Highlights
Excited to participate in SynBioBeta 2024 from May 6-9 in San Jose!
At bit.bio we're on a mission to engineer biology by developing and commercialising the synthetic biology paradigm of forward programming using transcription factors.
bit.bio's opti-ox™ technology applies a patented dual-safe harbour gene-targeting approach to inducibly express transcription factor combinations that program human induced pluripotent stem cells (iPSCs) into highly consistent and scalable human cell types.
Join me as we discuss how we're leveraging breakthroughs in synthetic biology to revolutionise cell coding and unlock a new era of medicine. I look forward to sharing insights on our latest research and the enormous possibilities when biotechnology meets scalability.
See you at SynBioBeta 2024 for a compelling look into the future of biotech!
https://lnkd.in/ejDcbWF8
#SynBioBeta2024 #SyntheticBiology #Health #Innovation #FutureOfMedicine #CellTherapies
Another great day at the ABI24 conference!
One highlight was engaging discussions with industry leaders like Christy Wyskiel, Stéphane Maikovsky, and Greg Raskin as they shed light on pioneering approaches to accelerating translation in biomedical research.
And let's not forget the captivating fireside chat with Jon Stonehouse, who shared the journey leading to a new medicine for a rare disease.
Networking with passionate individuals who share a common vision for innovation is what makes events like ABI24 invaluable.
#ABI24 #Biotech #Innovation #Health #SynBio #Networking
